Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_assertion type Assertion NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_head.
- NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_assertion description "[KRAS and BRAF mutations are common in LGSC, leading to clinical trials targeting the MAPK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_provenance.
- NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_assertion evidence source_evidence_literature NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_provenance.
- NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_assertion SIO_000772 25523272 NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_provenance.
- NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_assertion wasDerivedFrom befree-2016 NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_provenance.
- NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_assertion wasGeneratedBy ECO_0000203 NP1249371.RAff8Yr3yjxIK7j8E0dyZ-2izsJPTdRh2DmlQugk-LlRM130_provenance.